Evidence map›Paper›PMID 41509293›Full record

ArticlebioRxiv : the preprint server for biology2025

Transcriptome-wide mapping reveals an RNA-dependent mechanism of platinum cancer drugs.

Arun Krishnaraj, Xinrui Wei, Richi Thakral, Weiyi Guo, Siva Bala Subramaniyan, Xiaopei Zhang, Katelyn R Alley, Anqi Feng, Andrew Hoy, Douglas Kung and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Arun KrishnarajDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Xinrui WeiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Richi ThakralDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Weiyi GuoDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Siva Bala SubramaniyanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Xiaopei ZhangDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Katelyn R AlleyDepartment of Chemistry and Biochemistry, University of Oregon, Eugene, OR 97403, USA.
Anqi FengDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Andrew HoyDepartment of Chemistry, Georgetown University, Washington, DC 20057, USA.
Douglas KungDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Purushottam B TiwariDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Aykut ÜrenDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Rodrigo MaillardDepartment of Chemistry, Georgetown University, Washington, DC 20057, USA.
Victoria J DeRoseDepartment of Chemistry and Biochemistry, University of Oregon, Eugene, OR 97403, USA.ORCID 0000-0001-5761-671X
Sreejith J NairDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.ORCID 0000-0001-6295-1133

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
Regulatory Mechanisms Linking Spatial Gene Control and Genome OrganizationR35GM150636 · NIGMS · GEORGETOWN UNIVERSITY · PI Sreejith Janardhanan Nair · 2023 to 2026
$1.5M
Biacore 4000 High Throughput SystemS10OD019982 · OD · GEORGETOWN UNIVERSITY · PI UREN, AYKUT · 2015 to 2015
$484k
Inductively Coupled Plasma Mass Spectrometer for High Sensitivity Elemental AnalysisS10OD028492 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI RALLE, MARTINA · 2021 to 2021
$336k
NCI NIH HHS P30 CA051008NIGMS NIH HHS R35 GM150636NIH HHS S10 OD019982NIH HHS S10 OD028492
6 · The paper itself

Abstract

Small molecules developed to target proteins or DNA may also bind RNA, but the extent and biological significance of such interactions among oncology drugs remain poorly defined. Here, we systematically profiled RNA interactions of a cohort of clinically approved anticancer agents and uncovered widespread RNA off-targeting. Cisplatin, a frontline chemotherapeutic agent for solid tumors, has emerged as a prominent RNA-binding drug. While the primary mechanism of action of cisplatin has been attributed to DNA damage-induced apoptosis, it has also been shown to bind RNA molecules. However, the extent of RNA binding in cancer cells and its functional relevance in platinum-based chemotherapy remained unknown. To map specific RNA targets of cisplatin

Identifiers

PMID41509293
PMCPMC12776116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.